ProCE Banner Activity

CME

Lung Cancer Immunotherapy: Improving Patient Outcomes Across the Disease Continuum

Multimedia

Watch this on-demand webcast from a live satellite symposium on the use of immunotherapy for patients with lung cancer, including considerations in early-stage disease and treatment options for those with advanced NSCLC.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: January 17, 2023

Expiration: January 16, 2024

No longer available for credit.

Share

Faculty

Julie R. Brahmer

Julie R. Brahmer, MD, MSc, FASCO

Marilyn Meyerhoff Professor of Oncology
Co-Director, Thoracic Oncology
Co-Director, Upper Aerodigestive
Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Co-Leader of the Cancer Immunology Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Jarushka Naidoo

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Zofia Piotrowska

Zofia Piotrowska, MD, MHS

Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Regeneron Pharmaceuticals, Inc.

Target Audience

This educational program is intended to reach oncologists and other healthcare professionals working in the field of cancer immunotherapy involved in the care of patients with lung cancer.

Learning Objectives

  • Select optimal immune checkpoint inhibitor–based therapy for appropriate patients with NSCLC in the adjuvant and neoadjuvant settings, considering PD-L1 expression and expert recommendations
  • Evaluate the impact of immune checkpoint inhibitor treatment in the neoadjuvant and adjuvant settings on agent sequencing and treatment decisions for patients with advanced or metastatic NSCLC
  • Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy
  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of therapeutic strategies for all eligible patients with NSCLC, considering known racial-related and age-related disparities in care
  • Address factors that can influence response to immune checkpoint inhibitor therapy in individual patients with NSCLC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Julie R. Brahmer, MD, MSc, FASCO

Marilyn Meyerhoff Professor of Oncology
Co-Director, Thoracic Oncology
Co-Director, Upper Aerodigestive
Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Co-Leader of the Cancer Immunology Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Julie R. Brahmer, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Janssen, Lilly, Merck, Regeneron, Sanofi.

Faculty Disclosure

Primary Author

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS: researcher: Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Mirati, Novartis, Roche/Genentech; consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Kaleido Biosciences, Merck, NGM Pharmaceuticals, Novartis, Pfizer, Roche/Genentech, Takeda.

Zofia Piotrowska, MD, MHS

Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: consultant/advisor/speaker: AstraZeneca, Cullinan Oncology, C4 Therapeutics, Daiichi-Sankyo, Janssen, Lilly, Takeda; researcher: AbbVie, AstraZeneca, Blueprint, Cullinan, Daiichi-Sankyo, Janssen, Novartis, Spectrum, Takeda, Tesaro/GlaxoSmithKline.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 17, 2023, through January 16, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this program is to improve the knowledge and competence of learners in integrating immunotherapies into treatment plans for patients with NSCLC.